Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Weekly News Recap #Phispers
API SUPPLIERS
Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
With Fermion, start the journey of your innovative API.
Aarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
STOCK RECAP #PipelineProspector
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
APIs
Reply
26 Mar 2025
Reply
29 Sep 2022
Reply
14 Jan 2022
Reply
04 Dec 2021
Reply
18 Mar 2021
Reply
15 Sep 2018
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
US Patents
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
92
PharmaCompass offers a list of Osimertinib Mesylate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Osimertinib Mesylate manufacturer or Osimertinib Mesylate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Osimertinib Mesylate manufacturer or Osimertinib Mesylate supplier.
PharmaCompass also assists you with knowing the Osimertinib Mesylate API Price utilized in the formulation of products. Osimertinib Mesylate API Price is not always fixed or binding as the Osimertinib Mesylate Price is obtained through a variety of data sources. The Osimertinib Mesylate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Mereletinib mesylate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Mereletinib mesylate, including repackagers and relabelers. The FDA regulates Mereletinib mesylate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Mereletinib mesylate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Mereletinib mesylate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Mereletinib mesylate supplier is an individual or a company that provides Mereletinib mesylate active pharmaceutical ingredient (API) or Mereletinib mesylate finished formulations upon request. The Mereletinib mesylate suppliers may include Mereletinib mesylate API manufacturers, exporters, distributors and traders.
click here to find a list of Mereletinib mesylate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Mereletinib mesylate DMF (Drug Master File) is a document detailing the whole manufacturing process of Mereletinib mesylate active pharmaceutical ingredient (API) in detail. Different forms of Mereletinib mesylate DMFs exist exist since differing nations have different regulations, such as Mereletinib mesylate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Mereletinib mesylate DMF submitted to regulatory agencies in the US is known as a USDMF. Mereletinib mesylate USDMF includes data on Mereletinib mesylate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Mereletinib mesylate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Mereletinib mesylate suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Mereletinib mesylate Drug Master File in Korea (Mereletinib mesylate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Mereletinib mesylate. The MFDS reviews the Mereletinib mesylate KDMF as part of the drug registration process and uses the information provided in the Mereletinib mesylate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Mereletinib mesylate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Mereletinib mesylate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Mereletinib mesylate suppliers with KDMF on PharmaCompass.
A Mereletinib mesylate written confirmation (Mereletinib mesylate WC) is an official document issued by a regulatory agency to a Mereletinib mesylate manufacturer, verifying that the manufacturing facility of a Mereletinib mesylate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Mereletinib mesylate APIs or Mereletinib mesylate finished pharmaceutical products to another nation, regulatory agencies frequently require a Mereletinib mesylate WC (written confirmation) as part of the regulatory process.
click here to find a list of Mereletinib mesylate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Mereletinib mesylate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Mereletinib mesylate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Mereletinib mesylate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Mereletinib mesylate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Mereletinib mesylate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Mereletinib mesylate suppliers with NDC on PharmaCompass.
Mereletinib mesylate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Mereletinib mesylate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Mereletinib mesylate GMP manufacturer or Mereletinib mesylate GMP API supplier for your needs.
A Mereletinib mesylate CoA (Certificate of Analysis) is a formal document that attests to Mereletinib mesylate's compliance with Mereletinib mesylate specifications and serves as a tool for batch-level quality control.
Mereletinib mesylate CoA mostly includes findings from lab analyses of a specific batch. For each Mereletinib mesylate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Mereletinib mesylate may be tested according to a variety of international standards, such as European Pharmacopoeia (Mereletinib mesylate EP), Mereletinib mesylate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Mereletinib mesylate USP).
Comment (4)
